Nano Dimension Explores Merger with AI Health Firm, Pivoting from Additive Manufacturing

Nano Dimension has entered into a non-binding agreement to merge with Infinite Epigenetics, a company focused on artificial intelligence for preventive health and diagnostics. This proposed transaction represents a strategic pivot for Nano Dimension, moving away from its additive manufacturing investments and towards the high-growth healthcare AI sector.

Over the past year, Nano Dimension has been divesting its additive manufacturing assets. This includes the sale of businesses such as Desktop Metal, Fabrica, and Markforged, as well as its Additively Manufactured Electronics division. The decision to merge with Infinite Epigenetics follows a multi-month strategic review that evaluated approximately 20 companies, with Infinite Epigenetics identified as offering the most promising path for long-term value creation.

The merger, valued at up to $890 million, would leverage Nano Dimension's capital base and Nasdaq listing to support Infinite Epigenetics' mission. Existing Nano Dimension shareholders are expected to retain significant minority ownership in the combined entity, which will operate under the Infinite Epigenetics name and continue trading on the Nasdaq under the ticker symbol "IEAI." The combined company is projected to have over $400 million in cash at closing, providing substantial financial flexibility.

Under the terms of the agreement, Nano Dimension would acquire 100% of Infinite Epigenetics' equity. The combined entity aims to capitalize on the intersection of healthcare, biological data, and AI. While the parties are in a 30-day exclusivity period for due diligence and finalizing a definitive agreement, some shareholders, like Murchinson, have expressed concerns about potential resource misallocation and shareholder dilution.